PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30943275-1	2019	BACKGROUND: Based on non-clinical data, it is expected that azilsartan, an angiotensin II receptor blocker, will help improve insulin resistance in addition to its hypotensive action.	azilsartan	60-70	insulin	Homo sapiens	126-133	
35350513-2	2022	The objective of this study was to investigate and compare the effect of azilsartan and telmisartan on insulin resistance and metabolic biomarkers in patients with both hypertension and type 2 diabetes mellitus.	azilsartan	73-83	insulin	Homo sapiens	103-110	
30943275-2	2019	The present study is aimed to explore the effect of azilsartan compared to telmisartan on insulin sensitivity in hypertensive patients in the clinical setting.	azilsartan	52-62	insulin	Homo sapiens	90-97	
28290827-5	2016	Several preclinical studies have shown the additional properties of azilsartan, including increase of insulin sensitivity, cardio- and nephron protection in obesity.	azilsartan	68-78	insulin	Homo sapiens	102-109	
27731574-6	2016	Azilsartan"s very high affinity to and slow dissociation from the angiotensin 1 receptor (AT1R) along with its inverse agonistic properties make it a very good candidate for clinical effects beyond simple BP control, potentially counteracting cardiac hypertrophy, cardiac fibrosis and insulin resistance, together with improved reno-protection and atherosclerotic plaque stabilization.	azilsartan	0-10	insulin	Homo sapiens	285-292